Form 4 for TXG 10x Genomics, Inc.
Accepted 2026-08-26 16:46:04 ET · period of report 2026-08-24 · accession 0001610717-26-000392 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-26 16:46 | 2026-08-24 | TXG | Saxonov Serge | CEO, Dir | S - Sale | $63.02 | -18.5K | 1.09M | -2% | -$1.17M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2026-08-24 | S | D | 18,545 | $63.02 | 1,085,835 | D | — | — | (F1) The shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units. (F2) This transaction was executed in multiple trades at prices ranging from $63.0088 to $63.78, inclusive. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |